Try our Advanced Search for more refined results
Illumina, Inc. et al v. BGI Genomics Co., Ltd et al
Case Number:
3:19-cv-03770
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 14, 2022
Illumina Pays Complete Genomics $325M To End DNA IP Row
After a Delaware federal jury determined Illumina willfully infringed DNA sequencing patents held by Complete Genomics Inc. and owes $334 million — a figure that could be tripled — CGI's Chinese parent MGI said Thursday its rival agreed to pay $325 million to resolve the parties' fights in California and the First State.
-
March 28, 2022
Illumina Wins Injunction, Loses Triple Damages In BGI IP Case
Illumina can permanently bar its Chinese rival BGI Genomics from further infringing soon-to-expire patents behind its next-generation genome-sequencing technology, but can't triple its $8 million in damages awarded by a jury that determined BGI willfully infringed four out of five of those patents, a California federal judge ruled Sunday.
-
March 02, 2022
Illumina Looks To Triple $8M Win For BGI DNA IP Infringement
Illumina urged a California federal judge on Wednesday to order enhanced damages following a jury determining four out of five of the company's patents behind its next-generation genome-sequencing technology are valid and were willfully infringed by its Chinese rival BGI Genomics Co. Ltd., saying the $8 million in damages should be tripled.
-
November 30, 2021
Jury Says BGI Owes Illumina $8M For Infringing DNA Patents
A California federal jury determined Tuesday that four out of five of Illumina's patents behind its next-generation genome-sequencing technology were valid, finding that Illumina's Chinese rival BGI Genomics and its subsidiaries willfully infringed the patents and must pay Illumina $8 million in damages, according to a person familiar with the case.
-
November 22, 2021
Illumina's Bid For $25M Over DNA Tech Patents Goes To Jury
Attorneys for Illumina urged a California federal jury during closing arguments Monday to find that its Chinese rival BGI Genomics and its subsidiaries owe $25.4 million for willfully infringing Illumina patents on DNA sequencing technology, while BGI lawyers asked jurors to invalidate the patents as obvious.
-
November 19, 2021
Illumina Defends Validity Of DNA Sequencing Patents At Trial
A California federal jury heard testimony Friday from gene sequencing company Illumina's expert witness that 10 judges who previously upheld Illumina's patents behind its next-generation technology "got it right," one day after Chinese-owned DNA sequencing company Complete Genomics offered expert testimony that Illumina's patents are invalid as obvious.
-
November 17, 2021
'Laws Of Chemistry' Trump PTAB, Illumina Rival Tells Jury
The chief scientific officer of Chinese-owned DNA sequencing company Complete Genomics testified in a California federal jury trial Wednesday over rival Illumina's $25 million infringement suit that Federal Circuit and Patent Trial and Appeal Board judges wrongly upheld Illumina's patents, saying that "a thousand judges cannot overrule the laws of chemistry."
-
November 15, 2021
Illumina Tells Jury BGI Copied Its DNA Sequencing Patents
Counsel for DNA sequencing equipment supplier Illumina told a California federal jury Monday during opening statements in its $25 million suit that China-based BGI Genomics Co. Ltd. willfully infringed five of its DNA sequencing patents, while BGI's counsel told jurors that the patents couldn't have been infringed because they are invalid as obvious.
-
November 12, 2021
Illumina's DNA Patent Dispute With BGI Gets Calif. Jury
A California federal judge empaneled a nine-member jury Friday that will decide Illumina's allegations that Shenzhen-based BGI Genomics Co. Ltd. infringed five DNA sequencing patents after excusing some potential jurors for hardships or for their potential biases against Chinese companies.
-
September 10, 2020
Illumina Must Let Inventors Be Deposed In DNA Patent Suit
A California federal judge has shot down Illumina's attempt to scrap a magistrate judge's order requiring the biotechnology company to make the inventors of a DNA sequencing patent it's accusing BGI Genomics of infringing available for deposition.